骨质疏松唑来膦一酸安全性o.pptVIP

Version 11-Sep-07 造成骨质疏松症的主要危险因素有哪些呢？例如：生活饮食因素；内分泌因素；钙吸收异常；药物因素；维生素D缺乏；性别与种族的不同等均为骨质疏松症的主要危险因素。 大家好，很高兴有这个机会给大家介绍一个全新的绝经后骨质疏松症治疗产品，一年仅需给药一次即可提供全面骨骼保护作用的密固达。 Version 11-Sep-07 MA-* Zoledronic Acid Reduced Mean Serum β-CTX Assessment of biochemical markers of bone turnover such as serum ? C-telopeptide (?-CTX) can be considered in terms of efficacy and safety. (See also bone safety slides.) These markers were reduced with ZOL compared with placebo and the effect was maintained over time. The bone resorption marker serum ?-CTX was measured every 6 months in a subset of patients. Serum levels decreased significantly at 6 months among patients receiving ZOL 5 mg compared with placebo, and were maintained, on average, within the low end of the premenopausal range (0.04 to 0.18 ng/mL) throughout the course of the trial. Reductions in ?-CTX were significant compared with placebo at all time points (P .0001). At baseline, median levels of β-CTx were approximately 0.36-0.37 ng/mL for patients who received either ZOL or placebo. Six months after the first dose, median levels decreased to 0.085 ng/mL for patients in the ZOL group and 0.329 ng/mL for placebo-treated patients. All post-baseline visit median values for zoledronic acid-treated patients ranged between 0.04 and 0.18 ng/mL and were within the normal pre-menopausal range. Median values of approximately 0.4 ng/mL were maintained for placebo-treated patients. At Month 36, patients in the ZOL group had an approximate 55% (95% CI: 49% to 60%) greater rate of reduction in bone resorption as measured by serum β-CTx compared to placebo-treated patients Although values (on average) fall below the lower limit of the pre-menopausal range in the short-term following administration of ZOL 5 mg, they appear to increase within a month, and are within the pre-menopausal range by 6 months. At the end of every 12-month period, patients are on average well-established within the lower half of the pre-menopausal range. Refere